Uscom Limited · ASX:UCM
Uscom — Shareholder Meeting (November 2004)
29 slides from Uscom's shareholder meeting presentation, Nov 1, 2004
Slide 1: Welcome to the first Annual General Meeting of USCOM Limited
WELCOME ........ to the first Annual General Meeting of USCOM Limited
Slide 2: _UsCO
_UsCO
Slide 3: Since global marketing launch
—USCOMLTD | since global marketing launch
Slide 4: Highlights
Highlights Successful ASX Listing Marketing launch — 4 new staff Regulatory approvals — China, Europe $384,390 in sales revenue to June 30 $13.3 million cash at June 30, 2004
Slide 5: Science advanced, product advanced, new staff
Science advanced — 9 new studies Product advanced — 3 new engineers Total staff from 8 to 16 Directors held 7 meetings Corporate Governance policies
Slide 6: Directors
MrRomanZwoiensk Dr Fed Berry © MrLukeFay Mr Aob Philips Mr-Gary Davey
Slide 7: USCOM People: Engineering
USCOM People ome ENGINEERING =
Slide 8: USCOM People: Marketing
i a MARKETING
Slide 9: USCOM People: Operations & Administration
Slide 10: USCOM People
Slide 11: _UsCO
_UsCO
Slide 12: Proud of our achievements as a listed company
Proud of our achievements as a listed company. i A biotech company with proven product Proven demand & Proven revenue stream sninianieitinnnnanananauattatinnamnunmanenanniniai De Our objective: to build shareholder value in a great global business
Slide 13: The Listing
— USCOMLTD — scone “The Listing Listing Date: December 10, 2003 Cash Raised: $16,000,000 ASX ee ASX Code: UCM Shares Offered: 8,000,000 Total Shares: 38,000,000 Listing price: $2.00 Trading range: $2.11 - $3.90
Slide 14: USCOM (UCM) ASX Share Price: December to November 2004
USCOM (UCM) ASX Share Price: December 03 ~ November ‘04 Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Now
Slide 15: Analyst comment and share price growth
“This company has powerful technology that leaves the competitors for dead. Watch this one.” Southern Cross Equities Biotechnalagy Buzz, July 16, 2004 Share Price Growth to July 15 40.8% Outperform SCE Biotech Index 48.7%
Slide 16: Star performer since listing on the ASX
“USCOM has been a star performer since it listed on the ASX in the second quarter of 2003” Top 10 share price performers Q4 FYO4 0% 10% 20% 30% 40% 50% 60%
Slide 17: Financial results to June 2004
“USCOM LTD _ Cash in hand at June 30 $13,324,934 Revenue from product sales $384,390 Operating costs $2,057 070 Total costs $2,351,762 Total revenues $948,342 Net operating cash outflow ($1,467,103) Profit (Loss) after Income Tax ($1,251,684)
Slide 18: Financial Highlights: Quarter 1, Financial Year 2005
USCOMLTD _ " Financial Highlights ‘Quarter 1, Financial Year 2005: Cash in hand at September 30 $12,726,632 Cash receipts from customers $261,748 Net operating cash flows ($571,106)
Slide 19: Sales by region to date
China Japan South Asia S.E. Asia Australia UK Taiwan Korea iddie East TOTAL TO DATE:
Slide 20: Market Response
Market Response Great Ormond Street Hospital, London An USCOM customer and important paediatrics research site
Slide 21: ein i aris
It ein i aris Mill ill Dr Karsten Knobloch Hannover, Germany with USCOM in ER and retrieval helicopter
Slide 22: Dr Karsten Knobloch, Hannover
Dr Karsten Knobloch Hannover, Germany with USCOM in ER and retrieval helicopter
Slide 23: Dr Karsten Knobloch, Hannover
USCOMLTD Dr Karsten Knobloch Hannover, Germany with USCOM in ER and retrieval helicopter
Slide 24: Clinician endorsement of USCOM
| “USCOM has the potential to be a very important monitoring device, which can add a new dimension to the care of the patient with heart failure.” Dr Peter Lichtenthal, Assoc Prof Cardiathoracic Anaesthesia University of Arizona Health Sciences Centre
Slide 25: Product Development
Slide 26: Product Development
Slide 27: i
i
Slide 28: ‘USCOMLTD —
‘USCOMLTD —
Slide 29: USCOM Ltd
USCOM LTD -